These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35088395)

  • 1. DOAC Dipstick Testing Can Reliably Exclude the Presence of Clinically Relevant DOAC Concentrations in Circulation.
    Margetić S; Ćelap I; Huzjan AL; Puretić MB; Goreta SŠ; Glojnarić AČ; Brkljačić DD; Mioč P; Harenberg J; Hetjens S; Weiss C
    Thromb Haemost; 2022 Sep; 122(9):1542-1548. PubMed ID: 35088395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the DOAC Dipstick Test on Urine Samples With Chromogenic Substrate Methods on Plasma Samples in Outpatients Treated With Direct Oral Anticoagulants.
    Papageorgiou L; Hetjens S; Fareed J; Auge S; Tredler L; Harenberg J; Weiss C; Elalamy I; Gerotziafas GT
    Clin Appl Thromb Hemost; 2023; 29():10760296231179684. PubMed ID: 37278029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of DOAC Dipstick Test for Detecting Direct Oral Anticoagulants in Urine Compared with a Clinically Relevant Plasma Threshold Concentration.
    Örd L; Marandi T; Märk M; Raidjuk L; Kostjuk J; Banys V; Krause K; Pikta M
    Clin Appl Thromb Hemost; 2022; 28():10760296221084307. PubMed ID: 35249379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of a Qualitative Point-of-Care Strip Test to Detect DOAC Exposure at the Emergency Department: A Cohort-Type Cross-Sectional Diagnostic Accuracy Study.
    Merrelaar AE; Bögl MS; Buchtele N; Merrelaar M; Herkner H; Schoergenhofer C; Harenberg J; Douxfils J; Siriez R; Jilma B; Spiel AO; Schwameis M
    Thromb Haemost; 2022 Oct; 122(10):1723-1731. PubMed ID: 35785816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance Characteristics of DOAC Dipstick in Determining Direct Oral Anticoagulants in Urine.
    Harenberg J; Martini A; Du S; Krämer S; Weiss C; Hetjens S
    Clin Appl Thromb Hemost; 2021; 27():1076029621993550. PubMed ID: 33733904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
    J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
    Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
    Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial.
    Harenberg J; Beyer-Westendorf J; Crowther M; Douxfils J; Elalamy I; Verhamme P; Bauersachs R; Hetjens S; Weiss C;
    Thromb Haemost; 2020 Jan; 120(1):132-140. PubMed ID: 31705521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
    Nosáľ V; Petrovičová A; Škorňová I; Bolek T; Dluhá J; Stančiaková L; Sivák Š; Babálová L; Hajaš G; Staško J; Kubisz P; Kurča E; Samoš M; Mokáň M
    Eur J Clin Pharmacol; 2022 Apr; 78(4):557-564. PubMed ID: 35066599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
    Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
    Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Activators Ecarin and Factor Xa in Thrombelastography for Measurement of Anticoagulant Effect of Direct Oral Anticoagulants Using TEG 5000.
    Artang R; Brod C; Nielsen JD
    Semin Thromb Hemost; 2022 Oct; 48(7):808-813. PubMed ID: 36174600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
    Ząbczyk M; Kopytek M; Natorska J; Undas A
    Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban.
    Volod O; Rollins-Raval M; Goodwin AJ; Higgins RA; Long T; Chandler WL; Harris NS; Pham HP; Isom JA; Moser K; Olson JD; Smock KJ; VanSandt A; Wool G; Chen D
    Arch Pathol Lab Med; 2022 Jan; 146(2):145-153. PubMed ID: 34133726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
    Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study.
    Toorop MMA; van Rein N; Nierman MC; Vermaas HW; Huisman MV; van der Meer FJM; Cannegieter SC; Lijfering WM
    J Thromb Haemost; 2022 Jan; 20(1):92-103. PubMed ID: 34664401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples.
    De Kesel PM; Devreese KMJ
    J Thromb Haemost; 2020 Aug; 18(8):2003-2017. PubMed ID: 32400112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography.
    Artang R; Dias JD; Walsh M; Bliden K; Nielsen JD; Anderson M; Thurston BC; Tantry US; Hartmann J; Gurbel PA
    TH Open; 2021 Oct; 5(4):e570-e576. PubMed ID: 34984316
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.
    Harenberg J; Gosselin RC; Cuker A; Becattini C; Pabinger I; Poli S; Weitz J; Ageno W; Bauersachs R; Celap I; Choi P; Douketis J; Douxfils J; Elalamy I; Falanga A; Fareed J; Favaloro EJ; Gerotziafas G; Herkner H; Hetjens S; Heubner L; Klamroth R; Langer F; Lip GYH; Grory BM; Margetić S; Merrelaar A; Pikta M; Renne T; Schulman S; Schwameis M; Strbian D; Tafur A; Vassart J; Violi F; Walenga J; Weiss C
    Thromb Haemost; 2024 Aug; 124(8):770-777. PubMed ID: 38316416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.